Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.

about

Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.

Item

http://www.wikidata.org/entity/Q45070875

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Overall Safety of Ospemifene i ...... ntrolled Phase 2 and 3 Trials.

@en

Overall Safety of Ospemifene i ...... ntrolled Phase 2 and 3 Trials.

@nl

type

Item

label

Overall Safety of Ospemifene i ...... ntrolled Phase 2 and 3 Trials.

@en

Overall Safety of Ospemifene i ...... ntrolled Phase 2 and 3 Trials.

@nl

prefLabel

Overall Safety of Ospemifene i ...... ntrolled Phase 2 and 3 Trials.

@en

Overall Safety of Ospemifene i ...... ntrolled Phase 2 and 3 Trials.

@nl

P1476

Overall Safety of Ospemifene i ...... ntrolled Phase 2 and 3 Trials.

@en

P2093

Corrado Altomare

http://www.w3.org/2001/XMLSchema#string

James A Simon

http://www.w3.org/2001/XMLSchema#string

JoAnn V Pinkerton

http://www.w3.org/2001/XMLSchema#string

Susannah Cort

http://www.w3.org/2001/XMLSchema#string

Wei Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data.

Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data.

Vulvovaginal atrophy.

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.

Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.

Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial.

Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program.

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.

P304

14-23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/JWH.2017.6385

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29064335

http://www.w3.org/2001/XMLSchema#string

P921

placebo

phase II clinical trial

P932

5771532

http://www.w3.org/2001/XMLSchema#string